News · 26 weeks57+233%
2026-03-012026-08-23
Mix2890d
- Insider12(43%)
- Earnings6(21%)
- Other5(18%)
- SEC Filings5(18%)
Latest news
25 items- INSIDERChief Commercial Officer Powl Brian T. sold $51,663 worth of shares (4,345 units at $11.89) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 169,269 units (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERPresident and CEO Wilson Troy Edward bought $1,239,000 worth of shares (100,000 units at $12.39) (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERChief Legal Officer Bair Teresa Brophy sold $397,681 worth of shares (31,487 units at $12.63) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 195,444 units (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERPresident and CEO Wilson Troy Edward bought $1,112,000 worth of shares (100,000 units at $11.12) (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- SECSEC Form 10-Q filed by Kura Oncology Inc.10-Q - Kura Oncology, Inc. (0001422143) (Filer)
- SECKura Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kura Oncology, Inc. (0001422143) (Filer)
- PRKura Oncology Reports Second Quarter 2026 Financial Results– KOMZIFTI® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q – – KOMZIFTI® achieved majority share of new patient starts in R/R NPM1-m AML menin inhibitor class, establishing leadership after just two full quarters of launch – – Long-term, frontline AML data presented at EHA 2026 support potential for ziftomenib to transform standard of care and a $7 billion TAM – – Clinical updates support darlifarnib’s potential to enhance targeted therapies in RCC and KRAS-mutated tumors – – $519.0 million in cash, cash equivalents and short-term investments, plus $180 million in anticipated collaboration payments –
- PRKura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity– Publication details the discovery and preclinical characterization of ziftomenib, including its potency, selectivity, and mechanism of action – – Findings demonstrate differentiated menin binding and activity against certain resistance-associated mutations, further supporting ziftomenib’s potential across genetically defined acute leukemias – SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for cancer, today announced the publication of a manuscript in Blood, the flagship journal of the American Society of Hematology, detailing the discovery and preclinical development of ziftomenib, a potent and
- PRKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on August 3, 2026, the Compensation Committee of the Company’s Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 104,500 shares of common stock to six (6) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(
- PRKura Oncology to Report Second Quarter Financial ResultsSAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report its second quarter 2026 financial results after the close of the U.S financial markets on Wednesday, August 12, 2026. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update. The live webcast and archived replay of the event may be accessed on the Company’s website at www.kuraoncology.com under the Investors tab in the Events and Presentations section. About Kura OncologyKura Onc
- SECSEC Form 8-K filed by Kura Oncology Inc.8-K - Kura Oncology, Inc. (0001422143) (Filer)
- PRKura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026– Response rates up to 50% across evaluated dose levels and median PFS of 13 months observed in pre-treated, cabozantinib-naïve, locally advanced or metastatic ccRCC patients – – Activity compares favorably with historical outcomes for TKI and HIF-2α monotherapies -– – Combination was well tolerated and safety profile consistent with reported profiles of the individual agents – – Findings support potential for darlifarnib to enhance activity of VEGFR-targeted therapies in second- and third-line RCC settings – – Global, randomized Phase 1b study underway to establish recommended Phase 3 dose – – Investor call scheduled for today, July 27, 2026, at 5:00 a.m. PT / 8:00 a.m. ET – SAN DIEGO
- PRKura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients – – Updated data expected to support darlifarnib’s potential to enhance VEGFR-targeted therapy in ccRCC – – Global randomized Phase 1b study comparing darlifarnib plus cabozantinib versus cabozantinib alone is ongoing – – Results continue to support darlifarnib as a precision combination agent across multiple targeted therapy classes – – Virtual investor call on July 27, 2026 at 5:00 a.m. PT / 8:00 a.m. ET – SAN DIEGO, July 14, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company focused on prec
- PRKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, July 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on July 1, 2026, the Compensation Committee of the Company’s Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 68,750 shares of common stock to five (5) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4)
- INSIDERChief Medical Officer Leoni Mollie sold $834,283 worth of shares (84,929 units at $9.82) as part of a pre-agreed trading plan, decreasing direct ownership by 32% to 182,345 units (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- PRKura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial – – 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML – – High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing – – Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively – – 12-month survival rate, remission rates, MRD negativity, durability of CR and tolerability compare favorably to 7+3 precedents and strengthen confidence in ongoing KOMET-017 Phase 3 registrational study – – Kura to host a virtual investor event tomorro
- PRKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on June 1, 2026, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 53,000 shares of common stock to four (4) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4)
- INSIDERSEC Form 4 filed by Director Parks Diane L.4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERSEC Form 4 filed by Director Collins Helen Louise4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERSEC Form 4 filed by Director Hasnain Faheem4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERSEC Form 4 filed by Director Vasconcelles Michael4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERSEC Form 4 filed by Director Szela Mary T4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERSEC Form 4 filed by Director Malley Thomas4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERSEC Form 4 filed by Director Schafer Carol4 - Kura Oncology, Inc. (0001422143) (Issuer)
- SECSEC Form S-8 filed by Kura Oncology Inc.S-8 - Kura Oncology, Inc. (0001422143) (Filer)
KURA FAQ
6 questionsWhat does Kura Oncology Inc. do?
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute...Where does KURA stock trade?
Kura Oncology Inc. (KURA) is listed on NASDAQ.What sector and industry is KURA in?
Kura Oncology Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about KURA?
Kura Oncology Inc. has had 8 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $2300.00 price target on 2026-04-14. Recent price targets range from $1050.00 to $3100.00.What companies are similar to KURA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare KURA side-by-side with any of them on Quantisnow.How can I track KURA on Quantisnow?
Quantisnow aggregates Kura Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KURA to receive live email and push alerts on every new disclosure.